High-dose methylprednisolone plus rituximab (R-HDMP) is a useful treatment in chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients unfit for chemo-immunotherapy and has proven its utility on the treatment of CLL/SLL complicated by auto-immune cytopenias. We performed a retrospective, single-centre study, of CLL/SLL patients treated with R-HDMP for 9 years. Thirty-nine patients were included, median age at time of treatment was 77 years. Most patients had stage Rai III/IV and Binet C disease. Twenty-eight patients had relapsed/refractory disease at time of treatment with a median of 1 previous line of therapy; 53.8% had prior exposure to fludarabine and 25% to rituximab. Grade 3-4 neutropenia and thrombocytopenia were recorded in 10.2% and 17.9% patients, respectively. While on treatment, 51.3% had documented infectious complications, but no other non-haematological toxicities grades 3-4 were identified. Overall response rate was 64%. Median overall survival and progression-free survival were 24 and 13 months, respectively. Twenty four patients relapsed and 16 received another line of treatment after R-HDMP, with median time to next treatment of 13.5 months. Thirteen out of the 24 patients improved performance status and were subsequently considered fit for chemo-immunotherapy. R-HDMP is a valuable option for elderly and frail patients, with low risk of severe myelotoxicity and other severe adverse events. It was shown to work as a bridge to other lines of treatment, including chemo-immunotherapy.
Keywords: auto-immune haemolytic anaemia; chronic lymphocytic leukaemia; high-dose methylprednisolone; rituximab.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.